Innovation Pharmaceuticals Inc
OTC:IPIX
Decide at what price you'd be comfortable buying and we'll help you stay ready.
|
Johnson & Johnson
NYSE:JNJ
|
US |
|
Berkshire Hathaway Inc
NYSE:BRK.A
|
US |
|
Bank of America Corp
NYSE:BAC
|
US |
|
Mastercard Inc
NYSE:MA
|
US |
|
UnitedHealth Group Inc
NYSE:UNH
|
US |
|
Exxon Mobil Corp
NYSE:XOM
|
US |
|
Pfizer Inc
NYSE:PFE
|
US |
|
Nike Inc
NYSE:NKE
|
US |
|
Visa Inc
NYSE:V
|
US |
|
Alibaba Group Holding Ltd
NYSE:BABA
|
CN |
|
JPMorgan Chase & Co
NYSE:JPM
|
US |
|
Coca-Cola Co
NYSE:KO
|
US |
|
Verizon Communications Inc
NYSE:VZ
|
US |
|
Chevron Corp
NYSE:CVX
|
US |
|
Walt Disney Co
NYSE:DIS
|
US |
|
PayPal Holdings Inc
NASDAQ:PYPL
|
US |
P/B
Price to Book (P/B) ratio compares a company`s market value to its book value. It shows how much investors are paying for each dollar of net assets on the balance sheet.
Price to Book (P/B) ratio compares a company`s market value to its book value. It shows how much investors are paying for each dollar of net assets on the balance sheet.
Valuation Scenarios
If P/B returns to its 3-Year Average (0.2), the stock would be worth $0 (50% upside from current price).
| Scenario | P/B Value | Implied Price | Upside/Downside |
|---|---|---|---|
| Current Multiple | 0.1 | $0 |
0%
|
| 3-Year Average | 0.2 | $0 |
+50%
|
| 5-Year Average | 1 | $0.01 |
+630%
|
| Industry Average | 4.6 | $0.03 |
+3 364%
|
| Country Average | 2.5 | $0.02 |
+1 803%
|
Forward P/B
Today’s price vs future total equity
Peer Comparison
| Market Cap | P/B | P/E | ||||
|---|---|---|---|---|---|---|
| US |
|
Innovation Pharmaceuticals Inc
OTC:IPIX
|
518.3k USD | 0.1 | -0.1 | |
| FR |
|
Pharnext SCA
OTC:PNEXF
|
6T USD | -164 720.7 | -160 127.7 | |
| US |
|
Abbvie Inc
NYSE:ABBV
|
355.3B USD | -108.6 | 84.9 | |
| US |
|
Amgen Inc
NASDAQ:AMGN
|
187.9B USD | 21.7 | 24.3 | |
| US |
|
Gilead Sciences Inc
NASDAQ:GILD
|
165.8B USD | 7.3 | 19.5 | |
| US |
|
Vertex Pharmaceuticals Inc
NASDAQ:VRTX
|
110.5B USD | 5.9 | 28 | |
| US |
E
|
Epizyme Inc
F:EPE
|
94.1B EUR | -5 465.3 | -533.6 | |
| US |
|
Regeneron Pharmaceuticals Inc
NASDAQ:REGN
|
81B USD | 2.6 | 18 | |
| NL |
|
argenx SE
XBRU:ARGX
|
42.4B EUR | 6.8 | 38.4 | |
| US |
S
|
Seagen Inc
F:SGT
|
39.3B EUR | 18.2 | -61.8 | |
| AU |
|
CSL Ltd
ASX:CSL
|
62.2B AUD | 2.3 | 30.9 |
Market Distribution
| Min | 0 |
| 30th Percentile | 1.5 |
| Median | 2.5 |
| 70th Percentile | 4.8 |
| Max | 147 580.5 |
Other Multiples
Innovation Pharmaceuticals Inc
Glance View
Innovation Pharmaceuticals, Inc. is a clinical stage biotechnology company. The company is headquartered in Wakefield, Massachusetts and currently employs 4 full-time employees. The company went IPO on 2007-04-02. The firm is engaged in developing therapies with anti-inflammatory, antibiotic, antiviral, dermatology and oncology applications. The firm owns the right to numerous drug compounds, including Brilacidin, its lead drug in a class of compounds known as defensin-mimetics and Kevetrin (thioureidobutyronitrile), which is its lead anti-cancer compound. The firm's clinical trials focused on evaluating its drug candidates, including Kevetrin for the treatment of cancers and Brilacidin for treatments of Acute Bacterial Skin and Skin Structure Infection (ABSSSI), prevention of oral mucositis complicating chemoradiation treatment for cancer, and ulcerative colitis. The firm is focused on developing small molecule therapies to treat diseases in the areas of inflammatory diseases, cancer, dermatology and anti-infectives.
